glp-1 news employers Agonists: Managing Employee Health and Employer Costs GLP-1 drug use nearly quadruples

Developed by the Danish pharmaceutical company Novo Nordisk, Saxenda was approved by the FDA in December 2014 for the treatment of chronic weight management, combined with a reduced-calorie diet and physical activity

Common injection site reactions include mild redness, bruising, or temporary stinging

One of the main predictors of whether you are a viable candidate to need Semaglutide GLP-1 injections for weight loss is if you are considered obese, which is indicated by a body mass index of 30 or over

When beginning semaglutide treatment, its normal to have many questions

NHS services (such as NHS Online Pharmacy and NHS Pharmacy First) are available to patients in England only